Procainamide

CAS Number 51-06-9
Molecular Formula C13H21N3O
Molecular Weight 235.331 g/mol
InChI Key REQCZEXYDRLIBE-UHFFFAOYSA-N
LogP 0.88
Synonyms
  • Procainamide
  • 4-Amino-N-[2-(diethylamino)ethyl]benzamide
  • Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-
  • 51-06-9
  • 4-14-00-01154
  • Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-
  • 4-Amino-N-(diethylaminoethyl)benzamide
  • 4-Amino-N-[2-(diethylamino)ethyl]benzamide
  • Benzamide, p-amino-N-[2-(diethylamino)ethyl]-
  • Novocainamid
  • Novocainamide
  • Novocaine amide
  • Novocamid
  • NSC 27461
  • p-Aminobenzoic diethylaminoethylamide
  • p-Amino-N-(2-diethylaminoethyl)benzamide
  • Procainamid
  • procainamida
  • Procaine amide
  • Procanbid
  • 4-Amino-N-(2-(diethylamino)ethyl)benzamide
  • Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-
  • Biocoryl
  • BRN 2214285
  • EINECS 200-078-8
  • Procamide
  • 2-Diethylaminoethylamid kyseliny p-aminobenzoove
  • Procainamidum
  • UNII-L39WTC366D
  • Rhythmin

Applications:


USP Methods for the Separation of Propranolol and Procainamide using a Legacy L1 Column
  Application Notes: Propranolol is a common beta-blocker used for treating anxiety and hypertension, and procainamide is an antiarrhythmic drug. According to the USP methods, propranolol hydrochloride contain no less than 98% and no more than 101.5 percent of propranolol calculated on a dried basis. The USP HPLC method for the separation of phenylephrine and epinephrine was developed on Legacy L1 column according to the US Pharmacopeia methodology. L1 classification is assigned to reversed-phase HPLC column containing C18 ligand. Support for the material is spherical silica gel with particles size 3-10 um and pore size of 100-120A. Resolution between critical pairs corresponds to rules and specifications of USP. Application Columns: Legacy L1 C18 HPLC column Application compounds: Propranolol and procainamide Mobile phase: Water/MeOH/MeCN (70/70/90) with 7mM sodium lauryl sulfate and 11 mM phosphoric acid Detection technique: UV Reference: USP35: NF30

Condition

Column Legacy L1, 4.6x150 mm, 5 µm, 100A
Mobile Phase Water/MeOH/MeCN (70/70/90) with 7mM Sodium Lauryl   sulfate and 11   mM Phosphoric acid
Buffer Sodium Lauryl   Sulfate, Phosphoric acid
Flow Rate 1.0 ml/min
Detection UV, 270 nm
 

Description

Class of Compounds Drug, Beta blocker, Antiarrhythmic, Hydrophobic, Ionizable, Neutral
Analyzing Compounds Propranolol, Procainamide
 

Application Analytes:

Procainamide
Propranolol

USP Methods for the Separation of Propranolol and Procainamide Using the Legacy L1 Column
  Application Notes: Propranolol is a common beta-blocker used for treating anxiety and hypertension, and procainamide is an antiarrhythmic drug. According to the USP methods, propranolol hydrochloride contain no less than 98% and no more than 101.5 percent of propranolol calculated on a dried basis. The USP HPLC method for the separation of phenylephrine and epinephrine was developed on Legacy L1 column according to the US Pharmacopeia methodology. L1 classification is assigned to reversed-phase HPLC column containing C18 ligand. Support for the material is spherical silica gel with particles size 3-10 um and pore size of 100-120A. Resolution between critical pairs corresponds to rules and specifications of UPS. Reference: USP35: NF30

Condition

Column Legacy L1, 4.6x150 mm, 5 µm, 100A
Mobile Phase MeOH/H2O/MeOH
Buffer SLS
Flow Rate 1.0 ml/min
Detection UV, 270 nm
 

Description

Class of Compounds Drug, Antiarrhythmic, Hydrophobic, Ionizable
Analyzing Compounds Procainamide, Propranolol
 

Application Analytes:

Procainamide
Propranolol

USP Methods for the Analysis of Procainamide
  Application Notes: Procainamide is a common antiarrhythmic agent used to treat cardiac arrhythmias. According to USP methods procainamide hydrochloride contains not less than 98% and no more than 102% procainamide based on the dried basis. The USP HPLC method for the separation of procainamide and 4-aminobenzoic was developed on Legacy L1 column according to the US Pharmacopeia methodology. L1 classification is assigned to reversed-phase HPLC column containing C18 ligand. Support for the material is spherical silica gel with particles size 3-10 um and pore size of 100-120A. Resolution between critical pairs corresponds to rules and specifications of UPS. Reference: USP 35- NF30

Condition

Column Legacy L1, 4.6x150 mm, 5 µm, 100A
Mobile Phase MeOH/H2O - 60/40%
Buffer TEAPh pH 7.5
Flow Rate 1.0 ml/min
Detection UV, 270 nm
 

Description

Class of Compounds Drug, Antiarrhythmic, Hydrophobic, Ionizable
Analyzing Compounds Procainamide, 4-Aminobenzoic acid
 

Application Analytes:

4-Aminobenzoic Acid
Procainamide

USP Methods Analysis of Procainamide Legacy L1 Column
  Application Columns: Legacy L1 C18 HPLC column Application compounds: Procainamide and 4-aminobenzoic acid Mobile phase: WAter/MeOH/MeCN (70/70/90) with 7 mM sodium lauryl sulfate and 11mM phosphoric acid Detection technique: UV Reference: USP35: NF30

Condition

Column Legacy L1, 4.6x150 mm, 5 µm, 100A
Mobile Phase Water/MeOH/TEA (140/60/1)   adjusted to pH 7.5 with H3PO4
Buffer TEAPh
Flow Rate 1.5 ml/min
Detection UV, 230 nm
 

Description

Class of Compounds Drug, Nonsteroidal anti-inflammatory drug, Hydrophobic, Ionizable
Analyzing Compounds Ibuprofen, benzophenone
 

Application Analytes:

4-Aminobenzoic Acid
Procainamide
Procainamide Hydrochloride